Pascal Chanu has a Pharm.D., he started modeling with drug monitoring during hospital residency. He joined Roche Modeling & Simulation (M&S) group in 2003 as a postdoc and grew professionally up to Disease Area M&S expert. He moved to consultancy working for Pharsight (now Certara) in late 2008 where he aquired a large experience by supporting 35 drug development programs. He is back to the Roche group since 2016, working in Genentech Clinical Pharmacology department, as a group leader within the M&S group, focusing on oncology programs (heme and signaling pathways). His main motivation is to impact drug development using model-based approaches.